Brokerages expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to post ($0.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aevi Genomic Medicine’s earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.13). Aevi Genomic Medicine posted earnings per share of ($0.13) during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.4%. The business is expected to issue its next quarterly earnings results on Tuesday, March 12th.
According to Zacks, analysts expect that Aevi Genomic Medicine will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.53). For the next fiscal year, analysts expect that the business will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.29) to ($0.51). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03.
Shares of GNMX traded down $0.03 during mid-day trading on Friday, hitting $1.07. 51,900 shares of the company traded hands, compared to its average volume of 152,093. Aevi Genomic Medicine has a 1-year low of $0.83 and a 1-year high of $2.65. The company has a market cap of $71.24 million, a P/E ratio of -1.29 and a beta of 0.63.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Further Reading: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.